ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme — GBM

Glioblastoma Multiforme (GBM) Clinical Trial

Official title:
Phase 1B Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

Status Recruiting

Clinical Trial Summary

Assess safety and tolerability of ADI-PEG 20 in combination with radiotherapy and Temozolomide in newly diagnosed GBM

n/a

NCT number	NCT04587830
Study type	Interventional
Source	Polaris Group
Contact	John Bomalaski, M.D.
Phone	858-452-6688
Email	jbomalaski@polarispharma.com
Status	Recruiting
Phase	Phase 1
Start date	September 14, 2020
Completion date	May 30, 2027

See also
Status	Clinical Trial	Phase
Completed	`NCT01109095` - CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM	Phase 1
Active, not recruiting	`NCT04019002` - Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma	Phase 1
Terminated	`NCT02654041` - Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients	Phase 2
Recruiting	`NCT03213002` - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	Phase 1/Phase 2
Withdrawn	`NCT01788280` - Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab	Phase 2
Completed	`NCT01238237` - Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA	Phase 1
Completed	`NCT02202993` - TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM	Phase 1